Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Atara Biotherapeutics $175 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175…
NuVasive $400 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NuVasive,…
Penumbra $143.75 million follow-on offering
Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 865,963 shares of common stock for an…
1Life Healthcare $275 million convertible senior notes offering
Davis Polk advised the joint book-running managers and representatives of the initial purchasers in connection with a…
TransMedics Group $70 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering…
DENTSPLY SIRONA $750 million notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by…
Gamida Cell $60 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $60 million SEC-registered follow-on…
Turning Point Therapeutics $325 million stock offering
Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock…
ADC Therapeutics $267 million IPO
Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which…
Insulet $500 million stock offering
Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of…